Combining ePI and Structured Content AI for a Patient-Centric Future
Electronic Product Information (ePI) is revolutionizing how patients interact with drug information, offering a more accessible approach to managing product details, improving patient safety, and increasing global interoperability. Delivering ePI using an AI driver takes this innovation a step further, enabling organizations to create, manage, translate, and update content with heightened efficiency and accuracy. This guide explores how the integration of ePI and structured content AI tools fosters a patient-centric future, enhancing patient experiences, sustaining regulatory compliance, and streamlining operations.
Video Title Lorem ipsum dolor sit amet.
AI & Global Labeling: How Next-Gen Tools Are Streamlining Structured Component Authoring Effectively and Compliantly
Outside of the physical drug product itself, global labeling plays the most fundamental role in helping pharmaceutical companies deliver safe and effective therapies to the population. But the process behind global labeling—the authoring, editing, collaborating, translating, and publishing of drug labels—is both incredibly complex and time-consuming. This guide explores how AI-powered tools are helping teams simplify and accelerate their in-house authoring workflows, without sacrificing compliance. It also explains how, by using such tools, companies can transform not just the way they work but also the entire “last mile” of the drug development lifecycle.
AI & Global Labeling: How Next-Gen Tools Are Streamlining Structured Component Authoring Effectively and Compliantly
Outside of the physical drug product itself, global labeling plays the most fundamental role in helping pharmaceutical companies deliver safe and effective therapies to the population. But the process behind global labeling—the authoring, editing, collaborating, translating, and publishing of drug labels—is both incredibly complex and time-consuming. This guide explores how AI-powered tools are helping teams simplify and accelerate their in-house authoring workflows, without sacrificing compliance. It also explains how, by using such tools, companies can transform not just the way they work but also the entire “last mile” of the drug development lifecycle.
